A randomized study of 14 healthy volunteers and 30 patients with stable coronary artery disease taking aspirin showed that zalunfiban administered subcutaneously provided rapid, high-grade, limited-duration platelet inhibition while being well tolerated.

Link to Article

The open-label, randomized study assessed the onset of platelet aggregation inhibition after a single subcutaneous injection in 27 adults with STEMI just prior to PCI. Zalunfiban provided rapid and potent platelet inhibition, with a return to 50% of platelet function within about two hours.

Link to Article

CeleCor designs a randomized, placebo-controlled clinical trial to study zalunfiban or placebo, subcutaneously injected in STEMI patients treated in ambulances at the first point of contact. The primary endpoints were based on ECG and angiographic outcomes.

CeleCor modifies CeleBrate’s primary endpoints to a seven-point clinical scale and designates as a Phase 3 pivotal clinical trial after discussion with regulatory agencies.

Link to Clinical Trial